[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Schor NF: New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther; 2009 Apr;122(1):44-55
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.
  • Neuroblastoma, a peripheral nervous system tumor, is the most common extracranial solid tumor of childhood, and 65% of children with this tumor have only a 10 or 15% chance of living 5 years beyond the time of initial diagnosis.
  • Novel pharmacological approaches to nervous system tumors are urgently needed.
  • This review presents the role of and current challenges to pharmacotherapy of malignant tumors of the nervous system during childhood and adolescence and discusses novel approaches aimed at overcoming these challenges.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Spine (Phila Pa 1976). 2002 Jun 1;27(11):E284-7 [12045531.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Jul-Aug;19(5):337-45 [12078865.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):438-44 [12107547.001]
  • [Cites] Cancer Lett. 2002 Aug 8;182(1):53-9 [12175523.001]
  • [Cites] Bone Marrow Transplant. 2002 Aug;30(3):135-40 [12189530.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6132-7 [12203125.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4867-75 [12208732.001]
  • [Cites] Neurochem Res. 2002 Aug;27(7-8):665-74 [12374201.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6462-6 [12438236.001]
  • [Cites] Acta Paediatr Suppl. 2004 May;93(445):6-11 [15176712.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Nov;27(11):604-6 [16282892.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10183-7 [16288004.001]
  • [Cites] Neurobiol Dis. 2005 Dec;20(3):969-85 [16006137.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11735-42 [16357186.001]
  • [Cites] Curr Opin Investig Drugs. 2005 Dec;6(12):1200-14 [16370386.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Feb;57(3):357-67 [16001169.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2584-93 [16353135.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3238-47 [16540676.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):593-601 [16546973.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1750-9 [16551859.001]
  • [Cites] Cancer Lett. 2007 May 18;250(1):107-16 [17084521.001]
  • [Cites] Cancer Lett. 2007 May 18;250(1):17-24 [17141950.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 May;66(5):714-22 [17388794.001]
  • [Cites] J Bioenerg Biomembr. 2007 Feb;39(1):35-41 [17549641.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):119-29 [17361331.001]
  • [Cites] Lancet Oncol. 2007 Aug;8(8):685-95 [17644483.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10351-60 [17974978.001]
  • [Cites] Pediatr Neurosurg. 2008;44(2):97-103 [18230922.001]
  • [Cites] Pediatr Endocrinol Rev. 2008 Feb;5 Suppl 2:720-6 [18317443.001]
  • [Cites] Oncologist. 2008 Jun;13(6):690-9 [18586924.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):304-12 [18504417.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Sep;62(4):699-706 [18338171.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):599-607 [18577561.001]
  • [Cites] Neurology. 2008 Jul 29;71(5):365-73 [18663182.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1350-4 [18684041.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):99-103 [18566744.001]
  • [Cites] J Neurooncol. 2008 Oct;90(1):57-61 [18587536.001]
  • [Cites] Arch Med Res. 2008 Oct;39(7):655-62 [18760193.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6756-63 [12438277.001]
  • [Cites] Int J Cancer. 2003 Jan 20;103(3):387-92 [12471622.001]
  • [Cites] Cancer Detect Prev. 2002;26(6):444-53 [12507229.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1122-9 [12615731.001]
  • [Cites] Methods Mol Biol. 2003;218:71-83 [12616713.001]
  • [Cites] Am J Pathol. 2003 Jul;163(1):321-31 [12819037.001]
  • [Cites] Cancer Lett. 2003 Jul 18;197(1-2):131-5 [12880972.001]
  • [Cites] Cancer Lett. 2003 Jul 18;197(1-2):225-30 [12880986.001]
  • [Cites] Paediatr Drugs. 2003;5(8):533-43 [12895136.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Aug;25(8):601-5 [12902911.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 1;146(1):41-7 [14499695.001]
  • [Cites] Eur J Cancer. 2003 Oct;39(15):2234-8 [14522384.001]
  • [Cites] Mol Cancer Ther. 2003 Sep;2(9):911-7 [14555710.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):84-7 [14734455.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1773-80 [14996739.001]
  • [Cites] Neurosci Lett. 2007 Mar 6;414(2):110-4 [17293044.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):403-7 [16609952.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(1):1-8 [10647494.001]
  • [Cites] Pediatr Neurosurg. 2000 Jan;32(1):30-6 [10765136.001]
  • [Cites] J Clin Neurosci. 2000 Jan;7(1):20-3 [10847645.001]
  • [Cites] Drugs. 2000 Jun;59(6):1261-77 [10882162.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):597-602 [11107126.001]
  • [Cites] Med Pediatr Oncol. 2000 Dec;35(6):619-22 [11107131.001]
  • [Cites] Cancer Treat Rev. 2000 Dec;26(6):449-62 [11139374.001]
  • [Cites] Eur J Cancer. 2001 May;37(7):930-8 [11313183.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12(5):467-73 [11395575.001]
  • [Cites] Mol Med. 2001 Jun;7(6):393-400 [11474132.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6185-93 [11507071.001]
  • [Cites] J Mol Med (Berl). 2001 Aug;79(8):428-36 [11511973.001]
  • [Cites] Cell Signal. 2001 Jul;13(7):499-505 [11516625.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5865-77 [11593392.001]
  • [Cites] Mol Pharmacol. 2002 Jan;61(1):142-9 [11752215.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):128-33 [11857396.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Nov;23(8):500-5 [11878777.001]
  • [Cites] Mol Pharmacol. 2002 Apr;61(4):710-9 [11901208.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2336-42 [8625308.001]
  • [Cites] J Neurosci. 1996 Jun 15;16(12):3895-9 [8656283.001]
  • [Cites] Arch Biochem Biophys. 1997 Aug 15;344(2):413-23 [9264556.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Oct;5(5):471-80 [15544495.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:81-9 [15650234.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):181-7 [15690136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1933-8 [15671173.001]
  • [Cites] Proteomics. 2005 Feb;5(3):796-804 [15682461.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2320-30 [15743827.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2747-55 [15814657.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):547-53 [15827327.001]
  • [Cites] Methods Mol Med. 2005;111:267-81 [15911985.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):695-9 [15976334.001]
  • [Cites] Mol Cancer Ther. 2005 Jul;4(7):1128-35 [16020671.001]
  • [Cites] Oncogene. 2005 Jul 21;24(31):4965-74 [15897897.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7267-75 [16103078.001]
  • [Cites] J Neurochem. 2005 Sep;94(5):1448-56 [16001965.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):529-37 [16136028.001]
  • [Cites] Neurosci Lett. 2005 Dec 2;389(2):77-82 [16125842.001]
  • [Cites] Neoplasia. 2004 Jan-Feb;6(1):29-40 [15068669.001]
  • [Cites] BMC Cancer. 2003 Mar 26;3:10 [12697075.001]
  • [Cites] Brain Res. 2004 Jun 25;1012(1-2):13-21 [15158156.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1546-53 [16575006.001]
  • [Cites] Oncogene. 2006 May 25;25(22):3150-9 [16501609.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3485-93 [16740774.001]
  • [Cites] Hong Kong Med J. 2006 Jun;12(3):222-4 [16760552.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2885-90 [16682723.001]
  • [Cites] Cancer Invest. 2006 Apr-May;24(3):310-7 [16809160.001]
  • [Cites] Inorg Chem. 2006 Aug 7;45(16):6263-8 [16878935.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2241-50 [16985058.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1295-301 [17016664.001]
  • [Cites] Health Phys. 2007 Jan;92(1):33-9 [17164597.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):311-7 [16609945.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):964-74 [17215959.001]
  • [Cites] BMC Cancer. 2006;6:294 [17181871.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):376-83 [17264333.001]
  • [Cites] Biochem Pharmacol. 2007 Mar 1;73(5):643-55 [17150196.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1019-29 [17283134.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):911-20 [18716553.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):675-8 [18623206.001]
  • [Cites] J Cell Physiol. 2008 Dec;217(3):584-9 [18651562.001]
  • [Cites] J Neurosurg Pediatr. 2008 Oct;2(4):269-72 [18831662.001]
  • [Cites] Ann N Y Acad Sci. 2008 Sep;1138:22-31 [18837879.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):675-89 [18701711.001]
  • [Cites] J Child Neurol. 2008 Oct;23(10):1149-59 [18952581.001]
  • [Cites] J Child Neurol. 2008 Oct;23(10):1179-85 [18952584.001]
  • [Cites] Childs Nerv Syst. 2009 Jan;25(1):39-45 [18946672.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):1040-60 [18676356.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Jun;4(4):313-26 [15180497.001]
  • [Cites] Oncol Rep. 2004 Aug;12(2):403-9 [15254709.001]
  • [Cites] Chemotherapy. 2004 Jun;50(3):119-26 [15272226.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):425-9 [15266331.001]
  • [Cites] Neurosurg Focus. 2003 Nov 15;15(5):E13 [15323470.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1137-46 [15367708.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1457-66 [15467035.001]
  • [Cites] Cancer. 1971 Feb;27(2):374-8 [5100400.001]
  • [Cites] Natl Cancer Inst Monogr. 1976 Nov;44:49-54 [1030781.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5411-4 [2820568.001]
  • [Cites] Biochem Pharmacol. 1988 Feb 1;37(3):562-3 [2827689.001]
  • [Cites] J Clin Invest. 1992 Mar;89(3):774-81 [1531835.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3253-9 [8205548.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2576-82 [7780971.001]
  • [Cites] Cancer Res. 1996 Mar 15;56(6):1199-203 [8640797.001]
  • [Cites] Cancer Detect Prev. 2005;29(5):456-63 [16185816.001]
  • (PMID = 19318043.001).
  • [ISSN] 1879-016X
  • [Journal-full-title] Pharmacology & therapeutics
  • [ISO-abbreviation] Pharmacol. Ther.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS038569; United States / NINDS NIH HHS / NS / NS038569-10; United States / NCI NIH HHS / CA / CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289-09; United States / NCI NIH HHS / CA / R01 CA074289; United States / NINDS NIH HHS / NS / R01 NS038569-10
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 141
  • [Other-IDs] NLM/ NIHMS112040; NLM/ PMC2699440
  •  go-up   go-down


2. Delahaye S, Doz F, Sonigo P, Saada J, Mitanchez D, Sarnacki S, Benachi A: Prenatal diagnosis of dumbbell neuroblastoma. Ultrasound Obstet Gynecol; 2008 Jan;31(1):92-5
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal diagnosis of dumbbell neuroblastoma.
  • A neuroblastoma that develops in the sympathetic nodes can infiltrate the intervertebral foramina and invade the spinal canal, leading to spinal cord and nerve root compression and neurological impairment.
  • Dumbbell neuroblastomas are now considered to be unresectable tumors and preoperative chemotherapy is recommended.
  • We report the prenatal diagnosis of a dumbbell neuroblastoma successfully managed through premature delivery followed by immediate chemotherapy.
  • We suggest that delivering prematurely in such cases is only of benefit if chemotherapy can be administered under favorable conditions.
  • Chemotherapy should proceed immediately after delivery in order to reduce the size of the tumoral mass and its effects on the spine.
  • [MeSH-major] Fetal Diseases / diagnosis. Neuroblastoma / diagnosis. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Abortion, Induced / methods. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cesarean Section. Cyclophosphamide / administration & dosage. Female. Humans. Infant, Newborn. Methylprednisolone / administration & dosage. Pregnancy. Prenatal Diagnosis / methods. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 18058843.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


3. Miranda Soares PB, Quirino Filho S, Pereira DE Souza W, Ferreti Bonan PR, Martelli-Júnior H: Neuroblastoma in an adult: case report. Rev Med Chil; 2010 Sep;138(9):1131-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma in an adult: case report.
  • Neuroblastoma is the most common extracranial solid malignancy in children but rarely described in adults, being 10% of all cases diagnosed after the first decade of life.
  • Immunohistochemical analysis (negative for CD99, CD20, CD3 and desmin; and positive chromogranin, synaptophysin and NB84) confi rmed the diagnosis of neuroblastoma.
  • The patient was submitted to 12 cycles of chemotherapy receiving VAC (vincristine/doxorubicin/cyclophosphamide) interspersed with ICE (ifosfamide/mesna/etoposide) and doxorubicin was replaced by actinomycin in the 7th cycle.
  • She had good tolerance to this therapy, and has been clinically stable.
  • [MeSH-major] Brain Neoplasms / secondary. Neuroblastoma / pathology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Neoplasms / secondary. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Thoracic Vertebrae. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21249281.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; CAV protocol; ICE protocol 5
  •  go-up   go-down


Advertisement
4. Walter KN, Kratz C, Uhl M, Niemeyer C: Chemotherapy as a therapeutic option for congenital neuroblastoma complicated by paraplegia. Klin Padiatr; 2008 May-Jun;220(3):175-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as a therapeutic option for congenital neuroblastoma complicated by paraplegia.
  • BACKGROUND: Spinal compression can be a complication of neuroblastoma (NBL).
  • Delayed or insufficient treatment of this condition may lead to permanent neurological sequelae.
  • Therefore, appropriate treatment should be introduced promptly.
  • Therapeutic options include neurosurgery, chemotherapy, and radiation therapy.
  • Tumor size diminished quickly and neurological symptoms partly recovered after the patient received chemotherapy consisting of vincristine, doxorubicine, and cyclophosphamide.
  • CONCLUSION: Rapid initiation of chemotherapy was safe and effective in a neonate with NBL complicated by spinal cord compression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lumbar Vertebrae. Neuroblastoma / congenital. Neuroblastoma / drug therapy. Paraplegia / congenital. Spinal Cord Compression / congenital. Spinal Neoplasms / congenital. Spinal Neoplasms / drug therapy. Thoracic Vertebrae
  • [MeSH-minor] Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Neurologic Examination / drug effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Paraplegia.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478490.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


5. van Santen HM, Thonissen NM, de Kraker J, Vulsma T: Changes in thyroid hormone state in children receiving chemotherapy. Clin Endocrinol (Oxf); 2005 Feb;62(2):250-7
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in thyroid hormone state in children receiving chemotherapy.
  • Our goal was to quantify their changes in children with cancer during chemotherapy, and to correlate them to clinical condition and type of drugs.
  • DESIGN: During a 3-month period all patients admitted for chemotherapy to the paediatric oncology ward were evaluated for inclusion.
  • Patients with brain tumours, neuroblastoma (cranio)spinal irradiation and use of dexamethasone before the first blood sample were excluded.
  • MEASUREMENTS: Plasma concentrations of T4, T3, rT3, thyroxine-binding globulin (TBG), thyroglobulin (Tg), TSH, IGF-1, cortisol, PRL and physical well-being by means of questionnaires were measured before and during chemotherapy.
  • RESULTS: In 19 children, 46 courses of chemotherapy and 123 plasma samples were analysed.
  • During chemotherapy, mean concentrations of TSH, T3, Tg and cortisol decreased to 53, 67, 69 and 15% of the baseline value, respectively.
  • CONCLUSIONS: These results demonstrate that, in children, thyroid hormone state changes significantly during chemotherapy, apparently not related to physical well-being but to the drugs administered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy. Thyroid Hormones / blood
  • [MeSH-minor] Adolescent. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Child. Child, Preschool. Female. Glioma / blood. Glioma / drug therapy. Health Status. Humans. Hydrocortisone / blood. Insulin-Like Growth Factor I / analysis. Leukemia / blood. Leukemia / drug therapy. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prolactin / blood. Rhabdomyosarcoma / blood. Rhabdomyosarcoma / drug therapy. Sarcoma, Ewing / blood. Sarcoma, Ewing / drug therapy. Spinal Cord Neoplasms / blood. Spinal Cord Neoplasms / drug therapy. Thyroglobulin / analysis. Thyrotropin / blood. Thyroxine / blood. Thyroxine-Binding Proteins / analysis. Triiodothyronine / blood. Triiodothyronine, Reverse / blood

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15670204.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Thyroid Hormones; 0 / Thyroxine-Binding Proteins; 06LU7C9H1V / Triiodothyronine; 5817-39-0 / Triiodothyronine, Reverse; 67763-96-6 / Insulin-Like Growth Factor I; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; 9010-34-8 / Thyroglobulin; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


6. Yang Y, Liu Y, Wei P, Peng H, Winger R, Hussain RZ, Ben LH, Cravens PD, Gocke AR, Puttaparthi K, Racke MK, McTigue DM, Lovett-Racke AE: Silencing Nogo-A promotes functional recovery in demyelinating disease. Ann Neurol; 2010 Apr;67(4):498-507
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A small interfering RNA was developed to specifically suppress Nogo-A (siRNA-NogoA).
  • The therapeutic benefit appears to be mediated by axonal growth and repair, and is not attributable to changes in the encephalitogenic capacity of the myelin-specific T cells.
  • Silencing Nogo-A may be a therapeutic option for MS patients to prevent permanent functional deficits caused by immune-mediated axonal damage.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jan 27;403(6768):383-4 [10667780.001]
  • [Cites] J Exp Med. 2009 Jul 6;206(7):1549-64 [19546248.001]
  • [Cites] J Neurosci. 2000 Mar 15;20(6):2275-86 [10704503.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):341-6 [11201742.001]
  • [Cites] Microsc Res Tech. 2001 Mar 15;52(6):731-9 [11276125.001]
  • [Cites] Nature. 2002 May 30;417(6888):547-51 [12037567.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):941-4 [12068310.001]
  • [Cites] J Neurosci. 2002 Jul 1;22(13):5505-15 [12097502.001]
  • [Cites] Neurosci Lett. 2002 Aug 16;328(3):257-60 [12147320.001]
  • [Cites] Neuron. 2002 Jul 18;35(2):283-90 [12160746.001]
  • [Cites] Science. 2002 Aug 16;297(5584):1190-3 [12089450.001]
  • [Cites] J Cereb Blood Flow Metab. 2003 Feb;23(2):154-65 [12571447.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Mar 8;14(5):1139-43 [14980652.001]
  • [Cites] Nat Neurosci. 2004 Jul;7(7):736-44 [15184901.001]
  • [Cites] Lab Invest. 1987 Aug;57(2):157-67 [2441138.001]
  • [Cites] Lab Invest. 1989 May;60(5):714-25 [2716284.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):278-85 [9445407.001]
  • [Cites] Neurology. 1998 May;50(5):1266-72 [9595973.001]
  • [Cites] Immunity. 2004 Nov;21(5):719-31 [15539157.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):6981-92 [15557195.001]
  • [Cites] J Immunol. 2007 Feb 1;178(3):1341-8 [17237380.001]
  • [Cites] J Immunol. 2009 Apr 1;182(7):4479-87 [19299749.001]
  • [Cites] Exp Neurol. 2009 Jun;217(2):371-7 [19328785.001]
  • [Cites] Nature. 2000 Jan 27;403(6768):439-44 [10667797.001]
  • (PMID = 20437585.001).
  • [ISSN] 1531-8249
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS037513-09; United States / NINDS NIH HHS / NS / K24 NS044250-01; United States / NINDS NIH HHS / NS / K24 NS044250-05; United States / NINDS NIH HHS / NS / NS044250-05; United States / NINDS NIH HHS / NS / NS037513-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GAP-43 Protein; 0 / Glycoproteins; 0 / Myelin Basic Protein; 0 / Myelin Proteins; 0 / Myelin-Oligodendrocyte Glycoprotein; 0 / Nogo protein; 0 / Peptide Fragments; 0 / RNA, Small Interfering; 0 / myelin basic protein 1-11; 0 / myelin oligodendrocyte glycoprotein (35-55); 130068-27-8 / Interleukin-10; 57716-89-9 / 4-O-methyl-12-O-tetradecanoylphorbol 13-acetate; 82115-62-6 / Interferon-gamma; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ NIHMS220389; NLM/ PMC2929680
  •  go-up   go-down


7. Hussein HA, Goda HA: Paravertebral neurogenic tumors with intraspinal extension: preoperative evaluation and surgical approach. J Egypt Natl Canc Inst; 2009 Mar;21(1):12-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF WORK: To achieve adequate excision of paravertebral neurogenic tumors with intra spinal extension, safe decompression of spinal cord and preservation of spine stability.
  • Benign schwannoma were diagnosed in 5 cases, malignant schwannoma in 3, neurofibromatosis in one case, neuroblastoma in 3 cases, ganglioneuroblastoma in 2 cases and ganglioneuroma in 2 cases.
  • All cord compression manifestations improved postoperatively with perfect spine stability.
  • CONCLUSION: Para vertebral neurogenic tumors with intra spinal extension could be diagnosed and evaluated with very high accuracy using C-T in adjunct with MRI.
  • C-T guided biopsy can select patients with pathological diagnosis that could be sensitive to pre operative chemotherapy and/or radiotherapy to facilitate surgery.
  • KEY WORDS: Para vertebral - Neurogenic tumors - Intra spinal extension - Surgical approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601967.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


8. Indrawattana N, Sookrung N, Kulkeaw K, Seesuay W, Kongngoen T, Chongsa-nguan M, Tungtrongchitr A, Chaicumpa W: Human monoclonal ScFv that inhibits cellular entry and metalloprotease activity of tetanus neurotoxin. Asian Pac J Allergy Immunol; 2010 Mar;28(1):85-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TeNT produced in the infected tissue by the bacteria grown under anaerobic condition binds to ganglioside receptors of peripheral nerve, and endocytosed.
  • The A subunit exits from the endosome and undergoes a retrograde transport via the nerve axon to the spinal cord.
  • Current treatment mainstay of human tetanus is by passively administering anti-tetanus toxin produced from animals immunized with adjuvanted tetanus toxoid (TT).
  • There are several obstacles in production and use of the animal derived therapeutic antibody especially the allergic reaction and serum sickness induced by the host immune response to the foreign protein.
  • The animal antibody, mainly IgG, blocks nerve cell entry of the TeNT but does not neutralize the TeNT protease activity per se and cannot reverse the tetanus symptoms.
  • HuScFv from 4 selected huscfv-phagemid transformed E. coli clones inhibited binding of the native TeNT to retinoic acid pulsed human neuroblastoma cells when used at the molecular TeNT:HuScFv ratio of 1:100.
  • The HuScFv produced in this study either singly or in their suitable combination warrant developing further to a real use in humans as a surrogate of the animal antibody for treatment of tetanus.

  • Genetic Alliance. consumer health - Tetanus.
  • MedlinePlus Health Information. consumer health - Tetanus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527521.001).
  • [ISSN] 0125-877X
  • [Journal-full-title] Asian Pacific journal of allergy and immunology
  • [ISO-abbreviation] Asian Pac. J. Allergy Immunol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Peptide Library; 0 / R-SNARE Proteins; 0 / Receptors, Cell Surface; 0 / Single-Chain Antibodies; 0 / Tetanus Toxin; 11032-48-7 / tetanospasmin; EC 3.4.- / Metalloproteases; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


9. Sandberg DI, Bilsky MH, Kushner BH, Souweidane MM, Kramer K, Laquaglia MP, Panageas KS, Cheung NK: Treatment of spinal involvement in neuroblastoma patients. Pediatr Neurosurg; 2003 Dec;39(6):291-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of spinal involvement in neuroblastoma patients.
  • INTRODUCTION: Considerable controversy exists regarding the appropriate management of spinal involvement in neuroblastoma (NB) patients.
  • We review a large group of such patients and offer treatment recommendations.
  • Of 13 high- risk patients with normal neurologic examinations and no radiographic high-grade spinal cord compression (HGSCC), 12 were treated initially with chemotherapy, and only 1 demonstrated neurologic deterioration.
  • HGSCC was present in 18 patients with high-risk NB; 7 of 10 (70%) treated initially with chemotherapy and 6 of 6 (100%) managed initially with operation improved or remained stable.
  • All 9 low-risk patients with normal neurologic examinations and no HGSCC remained neurologically intact following operations (n = 7) or chemotherapy (n = 2).
  • All 4 low-risk patients with HGSCC treated with operations improved or remained stable, and 0 of 2 (0%) low-risk patients treated initially with chemotherapy remained stable.
  • Spinal deformities occurred in 2 of 16 patients (12.5%) treated nonoperatively and in 9 of 30 (30.0%) who underwent operations.
  • CONCLUSIONS: High-risk NB patients with spinal involvement but normal neurologic examinations should be offered chemotherapy.
  • High-risk patients with HGSCC may respond to chemotherapy, but a small percentage will require operations for progressive neurologic deficits.
  • Chemotherapy may be avoided in low-risk patients who are offered potentially curative operations.
  • Patients treated with operations for epidural disease are at high risk of subsequently developing spinal deformity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Spinal Cord Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Algorithms. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Spinal Cord / abnormalities. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14734862.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. De Bernardi B, Pianca C, Pistamiglio P, Veneselli E, Viscardi E, Pession A, Alvisi P, Carli M, Donfrancesco A, Casale F, Giuliano MG, di Montezemolo LC, Di Cataldo A, Lo Curto M, Bagnulo S, Schumacher RF, Tamburini A, Garaventa A, Clemente L, Bruzzi P: Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol; 2001 Jan 01;19(1):183-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases.
  • PURPOSE: To report on the treatment of patients with newly diagnosed neuroblastoma presenting with spinal cord compression (SCC).
  • PATIENTS AND METHODS: Of 1,462 children with neuroblastoma registered between 1979 and 1998, 76 (5.2%) presented with signs/symptoms of SCC, including motor deficit in 75 patients (mild in 43, moderate in 22, severe [ie, paraplegia] in 10), pain in 47, sphincteric deficit in 30, and sensory loss in 11.
  • Treatment of SCC consisted of radiotherapy in 11 patients, laminectomy in 32, and chemotherapy in 33.
  • Laminectomy was more frequently performed in cases with favorable disease stages and in those with severe motor deficit, whereas chemotherapy was preferred in patients with advanced disease.
  • In the other 66 patients, the neurologic response to treatment was comparable for the three therapeutic modalities.
  • All 11 patients treated by radiotherapy and 26 of 32 patients treated by laminectomy, but only two of 33 treated by chemotherapy, received additional therapy for SCC.
  • Fifty-four of 76 patients are alive at time of the analysis, with follow-up of 4 to 209 months (median, 139 months).
  • CONCLUSION: Radiotherapy, laminectomy, and chemotherapy showed comparable ability to relieve or improve SCC.
  • However, patients treated with chemotherapy usually did not require additional therapy, whereas patients treated either with radiotherapy or laminectomy commonly did.
  • [MeSH-major] Neuroblastoma / pathology. Neuroblastoma / therapy. Spinal Cord Compression / therapy. Spinal Cord Neoplasms / pathology. Spinal Cord Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Infant, Newborn. Laminectomy. Male. Neoplasm Invasiveness. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11134211.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Bourezgui M, Rafai MA, El Moutawakkil B, Boulaajaj FZ, Sibai M, Lezar S, Adil A, Benchkroun S, Kadiri R, Slassi I: [Cauda equina syndrome revealing neuroblastoma]. Rev Neurol (Paris); 2008 Dec;164(12):1048-51
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cauda equina syndrome revealing neuroblastoma].
  • INTRODUCTION: Neuroblastoma is the most common solid tumor of childhood.
  • Neurological involvement is rare resulting from cord or nerve compression.
  • Blood and urinary catecholamine level were elevated confirming the diagnosis of neuroblastoma.
  • She was treated with chemotherapy alone with partial neurological recovery.
  • DISCUSSION AND CONCLUSION: Cauda equina compression revealing neuroblastoma is exceptional especially at an early phase in the youngest patients.
  • Treatment is based on surgical resection and/or chemotherapy and/or radiation therapy.
  • [MeSH-major] Neuroblastoma / pathology. Polyradiculopathy / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Catecholamines / blood. Catecholamines / urine. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Spinal Cord / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18808776.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Catecholamines; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


12. Duhem-Tonnelle V, Vinchon M, Defachelles AS, Cotten A, Dhellemmes P: Mature neuroblastic tumors with spinal cord compression: report of five pediatric cases. Childs Nerv Syst; 2006 May;22(5):500-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature neuroblastic tumors with spinal cord compression: report of five pediatric cases.
  • BACKGROUND: Neuroblastic tumors cause spinal cord compression when they arise primarily in the spinal canal or invade it through the radicular foramen.
  • Whereas neuroblastomas (NB) are relatively common and are generally treated with chemotherapy, mature neuroblastic tumors (MNT), which include intermixed ganglioneuroblastomas (iGNB) and ganglioneuromas (GN), are less common and the role of surgery is more prominent.
  • MATERIALS AND METHODS: In order to increase our knowledge on MNT, we reviewed our database for cases operated for spinal cord compression in our department since the introduction of magnetic resonance imaging (MRI).
  • We treated four cases of NB and one case of iGNB presenting primarily with spinal cord compression.
  • REPORT OF CASES: MNT represented 10% of spinal tumors and 1.6% of all tumors of the nervous system in our pediatric neurosurgical practice.
  • The neurological and oncological outcomes were generally favorable after surgical resection, followed by orthotic treatment.
  • In one case with neurofibromatosis type 1, the tumor was inoperable and the child died of tumor progression several years later.
  • In case of subtotal removal, tumor remnants can stay stable without oncological treatment.
  • [MeSH-major] Neuroblastoma / complications. Spinal Cord Compression / etiology. Spinal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Nurs Mirror Midwives J. 1975 Nov 6;141(19):48-52 [1042886.001]
  • [Cites] Cancer. 2001 May 15;91(10 ):1905-13 [11346873.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):311-9 [8674009.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):215-20 [1574031.001]
  • [Cites] Pediatr Neurosurg. 2003 Dec;39(6):291-8 [14734862.001]
  • [Cites] J Child Neurol. 1998 Jul;13(7):356-8 [9701489.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):353-9 [10219337.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):579-83 [12948463.001]
  • [Cites] Radiographics. 2002 Jul-Aug;22(4):911-34 [12110723.001]
  • [Cites] Cancer. 1989 Mar 15;63(6):1211-4 [2917322.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1837-40 [4027922.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Apr;16(4 Suppl):875-7 [7611061.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1047-55 [11181668.001]
  • (PMID = 16369850.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Willems WF, Wieringa JW, Vermeulen RJ, Veenhoven RH: [Limping in toddlers due to disorders of the spine and spinal cord]. Ned Tijdschr Geneeskd; 2007 Oct 20;151(42):2297-301
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limping in toddlers due to disorders of the spine and spinal cord].
  • The authors describe three cases of limping in toddlers caused by infrequent spinal diseases.
  • The second patient, a 13-month-old boy, presented with limping caused by neuroblastoma with extensive bone metastasis.
  • Despite chemotherapy and partial resection of the neuroblastoma, the boy did not survive.
  • [MeSH-major] Astrocytoma / diagnosis. Bone Neoplasms / secondary. Discitis / diagnosis. Neuroblastoma / pathology. Spinal Diseases / diagnosis
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Female. Gait. Humans. Infant. Male. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064928.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


14. Pollono D, Tomarchia S, Drut R, Ibañez O, Ferreyra M, Cédola J: Spinal cord compression: a review of 70 pediatric patients. Pediatr Hematol Oncol; 2003 Sep;20(6):457-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression: a review of 70 pediatric patients.
  • The authors report their experience with 70 pediatric patients with spinal cord compression (SCC) due to malignancies identified among 898 patients with solid tumors.
  • An extradural tumor was the most frequent cause of SCC (71%); 54% of these were soft tissue sarcomas and neuroblastoma.
  • Most intradural tumors (70%) were outside the spinal cord, 9/12 being metastatic medulloblastomas.
  • Laminectomy was provided for patients with paraplegia of less than 96 h evolution; isolated recurrence of the main tumor; a primary spinal cord tumor; progression of neurologic symptoms after chemotherapy/radiotherapy; chemotherapy and radiotherapy-resistant tumor (when known); resection of a paraspinal tumor.
  • Twelve/twenty-one (57%) patients with paraplegia were able to walk after laminectomy only, while 14% (2/14) improved after chemotherapy and radiotherapy.
  • All patients (12) admitted without paraplegia and submitted to laminectomy were able to walk, and of these, 6 presented a primary spinal cord tumor.
  • The remaining had paraspinal tumors that extended to the spinal canal.
  • Almost 87% (20/23) of the patients without paraplegia who submitted to medical treatment were able to walk, while only one progressed to paraplegia.
  • Patients with SCC may entertain radio- and chemotherapy when harboring tumors responding to such therapies and present no evidence of neurologic damage progression.
  • [MeSH-major] Spinal Cord Compression / etiology. Spinal Cord Neoplasms / complications
  • [MeSH-minor] Adolescent. Algorithms. Argentina / epidemiology. Child. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Infant, Newborn. Male. Paraplegia / etiology. Survival Analysis. Treatment Outcome. Urinary Incontinence / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14631620.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


15. Nagasako H, Ijichi O, Shinkoda Y, Ikarimoto N, Kaji T, Nakame K, Takamatsu H, Kawano Y: Fetal ultrasonography to prevent irreversible neurological sequelae of neonatal neuroblastoma. Pediatr Hematol Oncol; 2004 Mar;21(2):157-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal ultrasonography to prevent irreversible neurological sequelae of neonatal neuroblastoma.
  • The baby was diagnosed as having neuroblastoma at the time of delivery at 39 weeks and its lower extremities were completely paralyzed.
  • The chemotherapy after birth was quite effective to reduce the mass volume but neurological sequelae failed to improve.
  • [MeSH-major] Neuroblastoma / complications. Neuroblastoma / ultrasonography. Paralysis / etiology. Ultrasonography, Prenatal
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Female. Fetal Diseases / ultrasonography. Humans. Infant, Newborn. Lower Extremity / physiopathology. Nervous System Diseases. Pregnancy. Spinal Cord Compression / embryology. Spinal Cord Compression / etiology. Spinal Cord Compression / prevention & control

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Paralysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15160514.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


16. Tsuchiya D, Kayama T, Kuchiki H, Sato S, Saito S: [A case of olfactory neuroblastoma with intracranial extension and distant metastasis]. No To Shinkei; 2000 Sep;52(9):811-6
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of olfactory neuroblastoma with intracranial extension and distant metastasis].
  • Olfactory neuroblastoma is a rare tumor originating in the upper nasal cavity.
  • We report a clinical case of olfactory neuroblastoma with intracranial extension and distant metastasis.
  • The tumor was removed totally and was histologically diagnosed as olfactory neuroblastoma.
  • Chemotherapy was administered using cisplatin and etoposide.
  • MRI demonstrated spinal dissemination.
  • Irradiation of the whole spinal cord was performed.
  • Olfactory neuroblastoma is a slow-growing tumor and is highly radiosensitive, but it rarely extends or develops multiple distant metastases and seldom shows a short survival time, as in our case.
  • A review of the literature documented responses in patients treated with a cisplatin-based drug combination.
  • We recommend systemic control using cisplatin-based chemotherapy in addition to irradiation to prevent local recurrence in cases of advanced or metastatic olfactory neuroblastoma.
  • [MeSH-major] Nasal Cavity. Neuroblastoma / pathology. Neuroblastoma / secondary. Nose Neoplasms / pathology. Nose Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11064869.001).
  • [ISSN] 0006-8969
  • [Journal-full-title] Nō to shinkei = Brain and nerve
  • [ISO-abbreviation] No To Shinkei
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


17. Hug EB, Nevinny-Stickel M, Fuss M, Miller DW, Schaefer RA, Slater JD: Conformal proton radiation treatment for retroperitoneal neuroblastoma: introduction of a novel technique. Med Pediatr Oncol; 2001 Jul;37(1):36-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conformal proton radiation treatment for retroperitoneal neuroblastoma: introduction of a novel technique.
  • BACKGROUND: Postoperative irradiation for locoregionally advanced neuroblastoma requires coverage of the paraspinal retroperitoneum.
  • The proximity of both kidneys and the liver, and a more complex target configuration, can pose a dosimetric challenge for conventional X-ray treatment and intraoperative irradiation.
  • We utilized proton radiation therapy (PRT) to reduce dose to uninvolved kidneys, liver, intestine, and spinal cord.
  • PROCEDURE: A 4-year-old male underwent PRT for neuroblastoma of the right adrenal gland, following chemotherapy and delayed surgical resection.
  • Clinical target volume (CTV), boost volume, and normal structures were outlined on the 3D treatment planning CT scan.
  • The patient received 25.2 CGE (cobalt Gray equivalent) to the CTV and 34.2 CGE to the boost region, using 1.8 CGE per fraction, five treatments per week.
  • Doses to 50% and 20% of the contralateral kidney in close proximity to deep left-side, paraspinal soft tissue involvement were restricted to 1 CGE and 10 CGE, respectively.
  • Using a patch technique, unique to charged particle therapy, the spinal cord was almost completely spared during boost volume irradiation.
  • CONCLUSIONS: PRT can achieve excellent dose conformity for advanced retroperitoneal, paraspinal lesions, while respecting normal tissue tolerance levels.
  • [MeSH-major] Neuroblastoma / radiotherapy. Protons. Radiotherapy, Conformal / methods. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Child, Preschool. Humans. Male. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Wiley-Liss, Inc.
  • (PMID = 11466721.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


18. Inagaki J, Yasui M, Sakata N, Inoue M, Yagi K, Kawa K: Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent. J Pediatr Hematol Oncol; 2005 Nov;27(11):604-6
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of chemoresistant stage 3 neuroblastoma using irinotecan as a single agent.
  • The authors describe a 1-year-old boy who was diagnosed with neuroblastoma by mass screening at age 6 months.
  • The tumor originated from the left retroperitoneum and extended over the midline, involving major vessels and invading the spine with compression of the spinal cord.
  • Although seven courses of chemotherapy consisting of vincristine sulfate, cyclophosphamide, pirarubicin hydrochloride, and cisplatin were administered, there was no reduction in tumor size or decrease in tumor markers.
  • This therapy was given a total of four courses every 4 weeks, with the tumor shrinking successively in each session.
  • Four years after treatment there is no sign of recurrence and the patient is doing well.
  • This case may be the first report showing the dramatic efficacy of irinotecan in the treatment of chemoresistant neuroblastoma without the use of other antitumor agents.
  • Irinotecan might be a promising drug in the management of patients with high-risk neuroblastoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Drug Resistance, Neoplasm. Neuroblastoma / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 3.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282892.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


19. Wilkins S, Pilling D, Buxton N, Pizer B: Pelvic teratoma with extensive spinal involvement in a neonate: an important differential diagnosis. Br J Neurosurg; 2008 Jun;22(3):426-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic teratoma with extensive spinal involvement in a neonate: an important differential diagnosis.
  • A 6-week-old girl presented with an abdominal mass and spinal cord compression.
  • Clinical and radiological features indicated a diagnosis of congenital neuroblastoma.
  • Histology revealed a diagnosis of germ cell tumour after therapy for neuroblastoma had been commenced.
  • [MeSH-major] Neuroblastoma / diagnosis. Pelvic Neoplasms / diagnosis. Retroperitoneal Neoplasms / diagnosis. Spinal Cord Compression / etiology. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Diagnosis, Differential. Etoposide / administration & dosage. Female. Humans. Hypertension / drug therapy. Infant. Neoplasm, Residual / diagnosis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18568732.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; JEB protocol
  •  go-up   go-down


20. Leung YM, Wu BT, Chen YC, Hung CH, Chen YW: Diphenidol inhibited sodium currents and produced spinal anesthesia. Neuropharmacology; 2010 Jun;58(7):1147-52
Hazardous Substances Data Bank. DIPHENIDOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diphenidol inhibited sodium currents and produced spinal anesthesia.
  • The aim of this study was to evaluate the effect of diphenidol on blocking Na(+) currents and spinal anesthesia.
  • We also evaluated the potencies and durations of diphenidol and lidocaine on spinal blockades of motor function, proprioception, and nociception in rats.
  • Lidocaine exhibited a concentration- and state-dependent effect on tonic blockade of voltage-gated Na(+) currents in mouse neuroblastoma N2A cells (IC(50) of 8.1 and 138.9 microM at holding potentials of -70 and -100 mV, respectively).
  • We also found that diphenidol acted like lidocaine and produced dose-related spinal blockades of motor function, proprioception and nociception.
  • Although diphenidol had similar potencies of spinal anesthesia compared with lidocaine it produced a much longer duration of spinal blockades than lidocaine.
  • Our results demonstrated that intrathecal diphenidol produced a long duration and similar potency on spinal anesthesia compared with lidocaine in rats.
  • [MeSH-major] Anesthetics, Local / pharmacology. Piperidines / pharmacology. Sodium / metabolism. Spinal Cord / drug effects. Spinal Cord / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Dose-Response Relationship, Drug. Lidocaine / administration & dosage. Lidocaine / chemistry. Lidocaine / pharmacology. Male. Membrane Potentials / drug effects. Mice. Motor Activity / drug effects. Neurons / drug effects. Neurons / physiology. Pain / drug therapy. Proprioception / drug effects. Rats. Rats, Sprague-Dawley. Time Factors

  • Hazardous Substances Data Bank. LIDOCAINE .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20176039.001).
  • [ISSN] 1873-7064
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Piperidines; 98PI200987 / Lidocaine; 9NEZ333N27 / Sodium; NQO8R319LY / diphenidol
  •  go-up   go-down


21. Gunes D, Uysal KM, Cetinkaya H, Tekin HG, Yuceer N, Sarialioglu F, Olgun N: Paravertebral malignant tumors of childhood: analysis of 28 pediatric patients. Childs Nerv Syst; 2009 Jan;25(1):63-9
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the clinical features and treatment results of the primary paravertebral malignant tumors (PMTs) in our department.
  • Tumor diagnoses were mostly neuroblastoma (46.4%) and soft tissue sarcomas (35.7%).
  • Sixteen had cord compression (CC; 13 clinical, three radiological CC).
  • Others were managed by pediatric oncology: five with corticosteroids+/-chemotherapy (one unresponsive), one with radiotherapy (RT), and two with surgery for the clinical CC.
  • Surgery was tumor excision in nine, laminectomy in nine, laminotomy in one, and delayed surgery after chemotherapy in two cases.
  • In chemotherapy and surgery groups, there were neurologic sequela associated with the advanced disease at diagnosis in 38% and 37%, respectively.
  • The CC caused by PMTs should be initially managed with corticosteroids +/- chemotherapy to avoid the adverse late effects of RT and surgery.
  • [MeSH-major] Neuroblastoma / therapy. Spinal Cord Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Recovery of Function / physiology. Retrospective Studies. Sarcoma / therapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):183-90 [11134211.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Jun;20(4):333-8 [12746166.001]
  • [Cites] Neurosurgery. 1991 Mar;28(3):349-52 [2011215.001]
  • [Cites] Spine (Phila Pa 1976). 2004 Jan 1;29(1):E4-6 [14699290.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Oct;25(10):822-3 [14528110.001]
  • [Cites] Neurochirurgie. 2001 Dec;47(6):552-6 [11915614.001]
  • [Cites] Spine (Phila Pa 1976). 1997 Feb 15;22(4):442-51 [9055374.001]
  • [Cites] Pediatr Hematol Oncol. 2003 Sep;20(6):457-66 [14631620.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):70-5 [1845814.001]
  • [Cites] Pediatr Neurol. 1994 Feb;10(1):40-3 [8198671.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1996;82(4):313-20 [8952911.001]
  • [Cites] J Neurosurg Pediatr. 2008 Jan;1(1):57-62 [18352804.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1047-55 [11181668.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):383-7 [9298274.001]
  • (PMID = 18843494.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Box M, Parks DA, Knight A, Hale C, Fishman PS, Fairweather NF: A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J Drug Target; 2003 Jul;11(6):333-43
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One goal of gene therapy is the targeted delivery of therapeutic genes to defined tissues.
  • One attractive target is the central nervous system as there are several neuronal degenerative diseases which may be amenable to gene therapy.
  • The yeast Gal4 DNA-binding domain enabled specific binding of DNA while the translocation domain from diphtheria toxin (DT) was included to facilitate crossing of the endosomal vesicle.
  • One multi-domain protein, containing all three of these domains, was found to transfect up to 8% of neuroblastoma N18-RE105 cells with marker genes.
  • The demonstration that this multi-domain protein can target genes specifically to neuronal cells is a first step in the development of novel vectors for the delivery of genes with therapeutic potential to diseased neuronal tissues.
  • [MeSH-minor] Animals. Biotin. Cell Line, Tumor. Drug Carriers. Enzyme-Linked Immunosorbent Assay. Escherichia coli / genetics. Gangliosides / metabolism. Genes, Reporter / genetics. Green Fluorescent Proteins. Humans. Hybridomas / metabolism. Luciferases / genetics. Luminescent Proteins / genetics. Mice. Neuroblastoma / metabolism. Plasmids / genetics. Polylysine / metabolism. Spinal Cord / cytology. Spinal Cord / drug effects. Spinal Cord / metabolism. Transfection

  • Genetic Alliance. consumer health - Tetanus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668054.001).
  • [ISSN] 1061-186X
  • [Journal-full-title] Journal of drug targeting
  • [ISO-abbreviation] J Drug Target
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Gangliosides; 0 / Luminescent Proteins; 0 / Peptide Fragments; 0 / Tetanus Toxin; 0 / tetanus toxin fragment C; 147336-22-9 / Green Fluorescent Proteins; 25104-18-1 / Polylysine; 6SO6U10H04 / Biotin; 9007-49-2 / DNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


23. Romero-Sandoval EA, Alique M, Moreno-Manzano V, Molina C, Lucio FJ, Herrero JF: The oral administration of retinoic acid enhances nociceptive withdrawal reflexes in rats with soft-tissue inflammation. Inflamm Res; 2004 Jul;53(7):297-303
Hazardous Substances Data Bank. CARRAGEENAN GUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oral administration of retinoic acid enhances nociceptive withdrawal reflexes in rats with soft-tissue inflammation.
  • SUBJECTS: Adult male Wistar rats and murine neuro2a and human SH-SY5Y neuroblastoma cells.
  • TREATMENT: Soft-tissue inflammation was induced by the intraplantar administration of 100 microl of carrageenan lambda.
  • The oral treatment with either ATRA or vehicle lasted for seven days and consisted in a dose of 15 mg/kg the first two days and a dose of 10 mg/kg the following five days.
  • Neuroblastoma cells were incubated for 16 h with ATRA.
  • The expression of COX enzymes was studied in spinal cords and neuroblastoma cells by western blot.
  • In neuroblastoma cells incubated with ATRA, a concentration-dependent increase in the expression of COX-2 protein was observed.
  • An increase in COX-2 expression in the lumbar spinal cord was also observed in animals treated with ATRA.
  • [MeSH-major] Administration, Oral. Inflammation / drug therapy. Pain. Tretinoin / administration & dosage
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Blotting, Western. Carrageenan / pharmacology. Cell Line, Tumor. Cyclooxygenase 1. Cyclooxygenase 2. Dose-Response Relationship, Drug. Hot Temperature. Humans. Isoenzymes / metabolism. Male. Membrane Proteins. Mice. Pain Measurement. Pressure. Prostaglandin-Endoperoxide Synthases / metabolism. Rats. Rats, Wistar. Reflex. Spinal Cord / drug effects. Spinal Cord / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15241564.001).
  • [ISSN] 1023-3830
  • [Journal-full-title] Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  • [ISO-abbreviation] Inflamm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Membrane Proteins; 5688UTC01R / Tretinoin; 9000-07-1 / Carrageenan; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS1 protein, human; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 1.14.99.1 / Ptgs1 protein, mouse; EC 1.14.99.1 / Ptgs1 protein, rat
  •  go-up   go-down


24. Aydin GB, Kutluk MT, Buyukpamukcu M, Akyuz C, Yalcin B, Varan A: Neurological complications of neuroblastic tumors: experience of a single center. Childs Nerv Syst; 2010 Mar;26(3):359-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHOD: Hospital file search was performed in patients with NT, and neurological complications, clinical, and treatment features were analyzed.
  • RESULTS: Out of 523 patients with NT, 19 patients had Horner's syndrome, 9 patients had opsoclonus-myoclonus-ataxia syndrome (OMA), 11 patients had central nervous system (CNS) involvement, and 49 patients had spinal cord compression (SCC) at diagnosis.
  • Survival rates were poor in patients with CNS involvement; all died at a median of 7.9 months after diagnosis.
  • The incidence of sequelae after laminectomy, radiotherapy, and chemotherapy were 46.2%, 66.6%, and 13.6%, respectively.
  • No differences in neurological improvement in patients with SCC were found between those treated with radiotherapy, laminectomy, or chemotherapy alone, but laminectomy and radiotherapy caused significant late sequelae.
  • Early diagnosis and proper management is critical to avoid long-term sequelae in patients with SCC.
  • [MeSH-major] Nervous System Diseases / complications. Nervous System Diseases / epidemiology. Neuroblastoma / complications. Neuroblastoma / epidemiology
  • [MeSH-minor] Child. Child, Preschool. Female. Follow-Up Studies. Humans. Incidence. Infant. Male. Prevalence. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neurologic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Neuropharmacol. 1992 Jun;15(3):186-228 [1394242.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):570-1 [14595720.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):183-90 [11134211.001]
  • [Cites] Med Pediatr Oncol. 2001 Jun;36(6):612-22 [11344492.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):181-9 [10363850.001]
  • [Cites] Cancer Lett. 2005 Oct 18;228(1-2):275-82 [15922508.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):155-65 [12833468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):865-9 [15708267.001]
  • [Cites] Cancer. 1996 Jul 15;78(2):311-9 [8674009.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Pediatr Neurosurg. 2003 Dec;39(6):291-8 [14734862.001]
  • [Cites] Cancer Lett. 2005 Oct 18;228(1-2):283-99 [15975710.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2330-5 [7666091.001]
  • [Cites] Med Pediatr Oncol. 1999 May;32(5):353-9 [10219337.001]
  • [Cites] Cancer. 1980 Jun 15;45(12 ):3095-101 [7388753.001]
  • [Cites] Cancer. 1971 Feb;27(2):374-8 [5100400.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Jul;31(7):471-80 [19564739.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1510-9 [11301399.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):177-83 [12909231.001]
  • [Cites] Med Pediatr Oncol. 2003 Feb;40(2):139 [12461808.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):149-55 [1734220.001]
  • [Cites] Childs Nerv Syst. 1998 Dec;14(12):713-8 [9881624.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1047-55 [11181668.001]
  • [Cites] Childs Nerv Syst. 2009 Jan;25(1):63-9 [18843494.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1999-2006 [1913549.001]
  • [Cites] Med Pediatr Oncol. 1997 Apr;28(4):284-8 [9078325.001]
  • (PMID = 19714340.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Huang X, Choi JK, Park SR, Ha Y, Park H, Yoon SH, Park HC, Park JO, Choi BH: GM-CSF inhibits apoptosis of neural cells via regulating the expression of apoptosis-related proteins. Neurosci Res; 2007 May;58(1):50-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, we reported that GM-CSF showed therapeutic effects on the spinal cord injury (SCI) in rat model possibly via its anti-apoptotic activity in the nervous system.
  • This study investigated the molecular mechanism of its anti-apoptotic and neuroprotective effects in N2a neuroblastoma cells and in rat SCI model.
  • In the Basso-Beattie-Bresnahan (BBB) locomotor test, the single GM-CSF administration showed better behavioral recovery than the untreated control only at early times within 1 week after injury.
  • [MeSH-major] Apoptosis / drug effects. Apoptosis Regulatory Proteins / drug effects. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Nerve Degeneration / drug therapy. Neurons / drug effects. Spinal Cord Injuries / drug therapy
  • [MeSH-minor] Animals. Brain Mapping. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / antagonists & inhibitors. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Models, Animal. Down-Regulation / drug effects. Down-Regulation / physiology. Enzyme Inhibitors / toxicity. Male. Mice. Neuroprotective Agents / pharmacology. Neuroprotective Agents / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / agonists. Proto-Oncogene Proteins c-bcl-2 / metabolism. Rats. Rats, Sprague-Dawley. Recovery of Function / drug effects. Recovery of Function / physiology. Staurosporine / antagonists & inhibitors. Staurosporine / toxicity. Tumor Suppressor Protein p53 / antagonists & inhibitors. Tumor Suppressor Protein p53 / metabolism. Up-Regulation / drug effects. Up-Regulation / physiology. bcl-2-Associated X Protein / antagonists & inhibitors. bcl-2-Associated X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17331604.001).
  • [ISSN] 0168-0102
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Bax protein, rat; 0 / Cdkn1a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Enzyme Inhibitors; 0 / Neuroprotective Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-2-Associated X Protein; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; H88EPA0A3N / Staurosporine
  •  go-up   go-down


26. Hemendinger RA, Armstrong EJ 3rd, Persinski R, Todd J, Mougeot JL, Volvovitz F, Rosenfeld J: Huperzine A provides neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death. Neurotox Res; 2008 Jan;13(1):49-61
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease resulting from the progressive loss of motor neurons in the spinal cord and brain.
  • The current study demonstrates for the first time that huperzine A, a potential neuroprotective agent, has the ability to protect a motor neuron-like cell line and motor neurons in spinal cord organotypic cultures from toxin-induced cell death.
  • The neuroblastoma-spinal motor neuron fusion cell line, NSC34 and rat spinal cord organotypic cultures (OTC) were exposed to cell death inducers for 24 h or 14 d, respectively, with and without pre-treatment with huperzine A.
  • This induction was significantly reduced with 2 h pre-treatment with 10 microM huperzine A (maximum, 35% rescue; p 0.05) following exposure to staurosporine, thapsigargin and H2O2 but not with CCCP.
  • In addition, pre-treatment with huperzine A dramatically improved motor neuron survival, based on choline acetyltransferase (ChAT) expression analysis in OTCs following exposure to THA, and compared to THA-treated control cultures.
  • These studies are currently being extended to include other inducers and with additional compounds as potential drug therapies that could be used in combination for the treatment of patients with ALS.
  • [MeSH-major] Apoptosis / drug effects. Motor Neurons / drug effects. Neuroprotective Agents / pharmacology. Sesquiterpenes / pharmacology. Spinal Cord / drug effects
  • [MeSH-minor] Alkaloids. Animals. Aspartic Acid / analogs & derivatives. Aspartic Acid / toxicity. Carbonyl Cyanide m-Chlorophenyl Hydrazone / toxicity. Cell Line. Drug Interactions. Enzyme Inhibitors / toxicity. Hydrogen Peroxide / toxicity. Ionophores / toxicity. Organ Culture Techniques. Oxidants / toxicity. Rats. Rats, Sprague-Dawley. Staurosporine / toxicity. Thapsigargin / toxicity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6591-5 [8393571.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2005 Aug;76(8):1046-57 [16024877.001]
  • [Cites] Exp Neurol. 2005 Dec;196 (2):235-43 [16242126.001]
  • [Cites] Biochem Pharmacol. 2005 Aug 1;70(3):470-80 [15950951.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54518-28 [15475565.001]
  • [Cites] Neurosignals. 2005;14(1-2):71-82 [15956816.001]
  • [Cites] Eur J Pharmacol. 1991 Oct 15;203(2):303-5 [1800123.001]
  • [Cites] FEBS Lett. 2002 Aug 28;526(1-3):21-5 [12208497.001]
  • [Cites] Basic Clin Pharmacol Toxicol. 2007 Mar;100(3):190-5 [17309523.001]
  • [Cites] Curr Opin Rheumatol. 2003 Nov;15(6):730-6 [14569202.001]
  • [Cites] J Alzheimers Dis. 2004 Dec;6(6):577-83; discussion 673-81 [15665397.001]
  • [Cites] J Neurosci Res. 2006 May 1;83(6):1048-57 [16493671.001]
  • [Cites] Eur J Pharmacol. 2001 Jun 15;421(3):149-56 [11516430.001]
  • [Cites] Neuron. 2006 Oct 5;52(1):39-59 [17015226.001]
  • [Cites] Mol Pathol. 2001 Dec;54(6):386-92 [11724913.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):823-35 [12598317.001]
  • [Cites] Methods Cell Biol. 1990;33:19-24 [2084468.001]
  • [Cites] J Neurosci. 2003 Mar 15;23 (6):2131-40 [12657672.001]
  • [Cites] J Neurosci Res. 2004 Apr 1;76(1):110-20 [15048935.001]
  • [Cites] Nature. 2000 May 18;405(6784):360-4 [10830966.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Oct;57(10):895-904 [9786240.001]
  • [Cites] Neurosci Lett. 2003 Apr 10;340(2):91-4 [12668244.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1425-31 [8676624.001]
  • [Cites] Biochemistry. 2002 Sep 3;41(35):10810-8 [12196020.001]
  • [Cites] Neurosci Lett. 2002 Jan 14;317(3):143-6 [11755260.001]
  • [Cites] J Appl Toxicol. 2001 Dec;21 Suppl 1:S47-51 [11920920.001]
  • [Cites] Eur J Pharmacol. 2005 Sep 5;519(1-2):9-15 [16111675.001]
  • [Cites] Eur J Pharmacol. 1993 Dec 21;250(3):473-6 [8112408.001]
  • [Cites] J Clin Invest. 2003 Jan;111(2):153-61 [12531867.001]
  • [Cites] Hum Gene Ther. 2005 Apr;16(4):509-21 [15871682.001]
  • [Cites] Acta Pharmacol Sin. 2007 Feb;28(2):273-8 [17241531.001]
  • [Cites] Neuroreport. 2001 Jul 20;12(10):2073-7 [11447310.001]
  • [Cites] J Neurosci Res. 1989 Oct;24(2):276-85 [2585551.001]
  • [Cites] J Neurosci Res. 2002 Jan 1;67(1):30-6 [11754078.001]
  • [Cites] Science. 2003 Oct 3;302(5642):113-7 [14526083.001]
  • (PMID = 18367440.001).
  • [ISSN] 1029-8428
  • [Journal-full-title] Neurotoxicity research
  • [ISO-abbreviation] Neurotox Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Enzyme Inhibitors; 0 / Ionophores; 0 / Neuroprotective Agents; 0 / Oxidants; 0 / Sesquiterpenes; 0111871I23 / huperzine A; 1860-87-3 / 3-hydroxyaspartic acid; 30KYC7MIAI / Aspartic Acid; 555-60-2 / Carbonyl Cyanide m-Chlorophenyl Hydrazone; 67526-95-8 / Thapsigargin; BBX060AN9V / Hydrogen Peroxide; H88EPA0A3N / Staurosporine
  •  go-up   go-down


27. Karatas Silistreli O, Ayhan M, Görgü M, Oztan Y, Sisman N: A primitive neuroectodermal tumor on the face: case report. Acta Chir Plast; 2005;47(2):38-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was claimed that this tumor originated from neuroectodermis and was different from the classical neuroblastoma.
  • The term primitive neuroectodermal tumor (PNET) involves a group of tumors of the soft tissue originating from neural crest and resulting from the brain, spinal cord and branches of the sympathetic nervous system.
  • It is treated with aggressive surgery as well as chemotherapy and radiotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033149.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


28. Rembach A, Turner BJ, Bruce S, Cheah IK, Scott RL, Lopes EC, Zagami CJ, Beart PM, Cheung NS, Langford SJ, Cheema SS: Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J Neurosci Res; 2004 Aug 15;77(4):573-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent proteomic analysis within our group on the copper zinc superoxide dismutase (SOD1)(G93A) transgenic mouse model of familial ALS (FALS) reveals a potentially deleterious upregulation of GluR3 in spinal cord compared to that in wild-type littermates.
  • This sequence significantly reduced levels of GluR3 protein and protected neuroblastoma x spinal cord (NSC-34) cells against death induced by the AMPA receptor-specific agonist (S)-5-fluorowillardiine.
  • Western blot analysis, however, did not reveal a significant reduction in GluR3 protein levels in whole extracts of the lumbar spinal cord.
  • These results suggest that interference with the GluR3 component of the AMPA receptor assembly may be a novel strategy for controlling excitotoxic destruction of motor neurons and may lead to new therapeutic opportunities for the treatment of human ALS.
  • [MeSH-major] Amyotrophic Lateral Sclerosis / therapy. Antisense Elements (Genetics) / pharmacology. Down-Regulation / drug effects. Peptide Nucleic Acids / pharmacology. Receptors, AMPA / antagonists & inhibitors. Superoxide Dismutase / metabolism
  • [MeSH-minor] Animals. Calcium / metabolism. Calcium / toxicity. Calcium Signaling / drug effects. Calcium Signaling / physiology. Cell Death / drug effects. Cell Death / genetics. Cells, Cultured. Disease Models, Animal. Disease Progression. Excitatory Amino Acid Agonists / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Mice. Mice, Transgenic. Nerve Degeneration / enzymology. Nerve Degeneration / genetics. Nerve Degeneration / therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15264227.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antisense Elements (Genetics); 0 / Excitatory Amino Acid Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Peptide Nucleic Acids; 0 / Receptors, AMPA; 0 / glutamate receptor ionotropic, AMPA 3; EC 1.15.1.- / SOD1 G93A protein; EC 1.15.1.1 / Superoxide Dismutase; SY7Q814VUP / Calcium
  •  go-up   go-down


29. Yalvaç ME, Ramazanoglu M, Tekguc M, Bayrak OF, Shafigullina AK, Salafutdinov II, Blatt NL, Kiyasov AP, Sahin F, Palotás A, Rizvanov AA: Human tooth germ stem cells preserve neuro-protective effects after long-term cryo-preservation. Curr Neurovasc Res; 2010 Feb;7(1):49-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of mesenchymal stem cells (MSCs) has been shown to be promising in chronic disorders such as diabetes, Alzheimer's dementia, Parkinson's disease, spinal cord injury and brain ischemia.
  • These findings confirm that hTGSCs preserve their major characteristics and exert neuro-protection after long-term cryo-preservation, suggesting that hTGSCs, harvested from young individuals and stored for possible use later as they grow old, might be employed in cellular therapy of age-related degenerative disorders.
  • [MeSH-minor] Annexin A5 / metabolism. Antigens, CD / genetics. Antigens, CD / metabolism. Antineoplastic Agents, Phytogenic / pharmacology. Caspase 3 / metabolism. Cell Differentiation. Cell Line, Tumor. Cell Proliferation. Cell Survival / drug effects. Child. Culture Media, Conditioned / pharmacology. Cytogenetic Analysis / methods. Drug Interactions. Female. Flow Cytometry / methods. Gene Expression Regulation / drug effects. Gene Expression Regulation / physiology. Humans. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Neuroblastoma. Neuroprotective Agents / pharmacology. Oxidative Stress / physiology. Paclitaxel / pharmacology. Time Factors

  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158462.001).
  • [ISSN] 1875-5739
  • [Journal-full-title] Current neurovascular research
  • [ISO-abbreviation] Curr Neurovasc Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antigens, CD; 0 / Antineoplastic Agents, Phytogenic; 0 / Culture Media, Conditioned; 0 / Nerve Tissue Proteins; 0 / Neuroprotective Agents; EC 3.4.22.- / Caspase 3; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement